Allison Whitten, PhD
Allison Whitten earned her PhD from Vanderbilt University in 2018 and continued her scientific training at Vanderbilt as a National Institute of Biomedical Imaging and Bioengineering (NIBIB) Postdoctoral Fellow. Her PhD and postdoctoral studies investigated the neurobiological causes of language impairments in neurological disorders. In 2020, she was awarded an AAAS Mass Media Fellowship to write for Discover Magazine. Her work has also appeared in WIRED, Quanta Magazine, Ars Technica, and more.
Articles by Allison Whitten, PhD
| 3 min read
The sensor could be used to enhance personalized medicine approaches for a variety of conditions.
| 5 min read
Pulmonary fibrosis patients have long suffered through side effects from their drugs. That could change with the potential for new inhaled versions in clinical trials.
| 3 min read
A new study showed that adding a drug to inhibit the OPA1 protein could reverse resistance to a frontline treatment in patients with AML.
| 3 min read
People with erythropoietic protoporphyria (EPP) must go to great lengths to avoid sun exposure. There have been no approved treatments that address the disease mechanism, but a new drug could change that.
| 6 min read
Vaxart aims to revolutionize immunization by replacing injections with easy-to-take tablets.
| 3 min read
A novel eye drop from LENZ Therapeutics represents the first time the FDA has approved aceclidine, a cholinergic agonist, in any drug.
| 3 min read
New research suggests an unexpected role for T cells during a tumor’s evolution from benign to malignant.
| 3 min read
Blood tests can’t diagnose Alzheimer’s disease yet, but one is already approved and more are on the way.
| 2 min read
Researchers showed that in rodent models, a glia-produced molecule could regulate weight loss and glucose metabolism without gastrointestinal symptoms.
| 2 min read
Qfitlia, an RNAi therapeutic given every two months, is the first to target the antithrombin protein instead of missing clotting factors in the blood.
| 5 min read
Advances in screening and protein targeting are reviving interest in molecular glues as a strategy to tackle previously undruggable diseases.
| 8 min read
By starting with T cells from healthy donors, Allogene is manufacturing off-the-shelf CAR T cell therapies that patients don’t have to wait for.
